Stem Cell Seminar Features International Insights on ACL Treatment
News related to:Miracell U.S. Inc · 3 min read
LOS ANGELES, Oct. 14, 2026 /CourierPR/ -- Miracell U.S. Inc., the U.S. subsidiary of South Korean stem cell technology pioneer Miracell, is hosting "Stem Cell Science Day 2026," a specialized seminar on regenerative medicine, in Los Angeles, California, on Sunday, November 1. The seminar will bring together medical professionals from South Korea and the United States to present the latest research developments and clinical findings in stem cell-based therapies. Participants will explore real-world clinical applications and potential healthcare integration of Miracell's proprietary SMART M-CELL system in the U.S.
The seminar, titled "Stem Cell Science Day 2026," will take place from 1:00 p.m. to 7:00 p.m. at The Equitable Building (14th Floor) on Wilshire Boulevard in Los Angeles. It is open to healthcare professionals, including physicians (MD/DO), nurse practitioners (NP), physician assistants (PA), and registered nurses (RN), free of charge. The event will feature leading medical experts from South Korea and the United States who will present the latest research and clinical outcomes in regenerative medicine.
Leading Medical Experts to Present Advances in Regenerative Medicine
The seminar features three prominent practitioners from South Korea and the United States who will present emerging research and clinical outcomes across women's health, orthopedics, and anti-aging medicine. Sung-Wook Choi, M.D., Ph.D., Professor of Orthopedic Surgery at Jeju National University, will share clinical cases and therapeutic applications using Miracell's SMART M-CELL stem cell isolation and concentration system.
International Study Highlights Clinical Outcomes of SMART M-CELL for ACL Injuries
Miracell's SMART M-CELL system continues to gain global academic traction. A research team led by Patrick Weninger, M.D., an orthopedic specialist in Vienna, Austria, recently published findings from a clinical study involving 47 patients with anterior cruciate ligament (ACL) ruptures (mean age: 28.1 years) in the SCIE-indexed Indian Journal of Orthopaedics (July 2026). Using the SMART M-CELL system, researchers isolated and concentrated CD34+-containing blood-derived stem cells (BSCs) from each patient. Combined with PRP, the preparation was administered to the injured ligament in a single non-surgical session. Over a 12-month follow-up period, 46 out of 47 patients successfully returned to their pre-injury sports activity levels, demonstrating significant pain reduction, improved knee function, and positive structural restoration on MRI scans. These findings highlight the potential of a tissue-preserving, biological approach to ACL management, offering an effective non-surgical alternative for selected patients.
U.S. Expansion and Global Collaboration
SMART M-CELL is an advanced cell separation system engineered to process autologous blood and bone marrow. In April 2026, Miracell received 510(k) clearance from the U.S. FDA for its SMART M-CELL blood-derived stem cell (BSC) and bone marrow-derived stem cell (BmSC) concentration systems and dedicated kits, establishing a solid foundation for its entry into the U.S. market. Beyond clinical presentations, Stem Cell Science Day 2026 will feature panel discussions, interactive Q&A sessions, one-on-one consultations, and networking opportunities designed to foster long-term international collaboration in regenerative medicine. The event will take place on Sunday, November 1, 2026, from 1:00 p.m. to 7:00 p.m. PDT (Los Angeles time) at The Equitable Building, 14th Floor, 3435 Wilshire Blvd., Suite 1400, Los Angeles, CA 90010. The event is open to physicians and licensed healthcare professionals (MD, DO, NP, PA, RN) free of charge, with limited seating and advance registration required. The website for the event is www.mira-cell.us.
Additional logistical details:
- The Austrian clinical study on 47 ACL rupture patients treated with SMART M-CELL was published in the Indian Journal of Orthopaedics in July 2026. - The SMART M-CELL system is engineered to process autologous blood and bone marrow. - In April 2026, Miracell received 510(k) clearance from the U.S. FDA for its SMART M-CELL blood-derived stem cell (BSC) and bone marrow-derived stem cell (BmSC) concentration systems and dedicated kits. - The seminar will feature panel discussions, interactive Q&A sessions, one-on-one consultations, and networking opportunities.